AOD-9604

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic modified fragment of human growth hormone, comprising amino acids 177–191 of the hGH sequence with an additional tyrosine residue at the N-terminus. Also referred to as the AOD 9604 peptide, this compound is closely related to hGH fragment 176 191 — the C-terminal region responsible for growth hormone’s fat-metabolising properties. Originally developed by Metabolic Pharmaceuticals in Australia as a potential anti-obesity therapeutic, aod-9604 peptide was designed to isolate the lipolytic (fat-metabolising) domain of hGH from its growth-promoting and diabetogenic properties.[1][3]

The distinction between AOD-9604 and full hGH is fundamental to understanding this AOD peptide. Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor, does not stimulate IGF-1 production, and does not promote skeletal or tissue growth. Preclinical research has demonstrated that it retains the C-terminal fragment’s ability to stimulate fat oxidation and inhibit lipogenesis — the conversion of food into stored fat — through a mechanism that operates independently of the classical GH-receptor signalling axis.[1][2]

For researchers asking what is AOD 9604 and why it attracts attention: despite promising preclinical data, AOD-9604’s clinical development for obesity stalled after Phase 2 trials showed safety but inconsistent efficacy signals. More recently, emerging research has investigated AOD-9604 in cartilage repair contexts, adding a secondary research angle to a compound that remains one of the most frequently discussed peptides in the research community.[4][5]

Compound Profile

What Does AOD-9604 Actually Do?

The core research interest in AOD-9604 centres on fat metabolism. Preclinical data consistently demonstrates two complementary effects: stimulation of lipolysis (the breakdown of stored fat for energy) and inhibition of lipogenesis (the synthesis and storage of new fat). These are the same metabolic effects attributed to the C-terminal region of full-length human growth hormone — but isolated from the growth-promoting, insulin-disrupting, and IGF-1-stimulating properties that make full hGH metabolically complicated.[1][2][3]

Importantly, AOD-9604 does not appear to affect blood glucose levels, insulin sensitivity, or circulating IGF-1 concentrations in the research models studied. This is a significant distinction from growth hormone-releasing peptides and full hGH, which carry metabolic side-effect profiles linked to glucose dysregulation and insulin resistance. The selective fat-metabolism signal without broader hormonal disruption was the pharmacological rationale behind AOD-9604’s development as an anti-obesity candidate.[3]

Beyond fat metabolism, a more recent line of investigation has explored AOD-9604 in the context of cartilage and joint health. A 2015 study in a rabbit osteoarthritis model demonstrated potential chondroprotective effects when administered intra-articularly, opening a secondary research direction that remains in early stages.[4][5]

How AOD-9604 Works

AOD-9604’s mechanism is rooted in the biology of human growth hormone’s C-terminal domain. The AOD 9604 peptide derives from the 177–191 amino acid region of hGH — also known as hGH fragment 176-191 or simply frag 176 191 — which has long been identified as the fragment responsible for the hormone’s lipolytic activity. By synthesising this fragment — with an N-terminal tyrosine to improve stability — researchers created a molecule that reproduces hGH’s fat-metabolism signalling without engaging the GH receptor itself.[1][3]

The pathway through which AOD-9604 exerts its effects appears distinct from the classical GH-receptor/JAK-STAT axis. Heffernan et al. (2001) provided key evidence using both obese mice and beta-3 adrenergic receptor (β3-AR) knockout mice. In normal obese mice, chronic AOD-9604 treatment increased fat oxidation and reduced body weight. In β3-AR knockout mice, these effects were significantly diminished — implicating the beta-3 adrenergic receptor pathway in AOD-9604’s lipolytic mechanism.[2]

Ng et al. (2000) confirmed that AOD-9604 stimulated lipolysis in adipose tissue without the diabetogenic effects seen with full hGH, leaving glucose homeostasis, insulin signalling, and IGF-1 levels unaffected.[3] Cox et al. (2015) characterised AOD-9604’s detection and in vitro metabolism, providing pharmacological profiling relevant to anti-doping surveillance.[6]

Fat Loss & Recomp Context

Fat loss and body recomposition is AOD-9604’s primary research domain — the pharmacological purpose for which this AOD peptide was originally designed. The preclinical evidence base is centred on obese rodent models, where AOD-9604 demonstrated consistent fat oxidation enhancement and body weight reduction over chronic treatment protocols.[1][2]

Heffernan et al. (2001) reported significant increases in fat oxidation and weight loss in obese mice treated with AOD-9604, with effects comparable to full-length hGH but without IGF-1 elevation or insulin resistance.[1] The same group’s β3-AR knockout study confirmed that AOD-9604’s fat-loss effects were mediated through adrenergic signalling rather than the GH receptor.[2] These findings established a compelling rationale: selective fat metabolism enhancement without the metabolic complications of full growth hormone.

However, the translation from preclinical promise to clinical outcome has been disappointing. Human Phase 2 trials conducted by Metabolic Pharmaceuticals demonstrated that AOD-9604 was well-tolerated and safe across multiple endpoints, but efficacy signals for weight loss were modest and inconsistent. The programme did not advance to Phase 3. This gap between robust preclinical data and underwhelming clinical results remains a central interpretive challenge for AOD-9604 research — and should calibrate expectations for anyone evaluating the aod 9604 fat loss and aod 9604 weight loss evidence.

Body Recomp Context

The body recomposition interest in the AOD 9604 peptide stems from its fat-selective mechanism of action. In preclinical models, AOD-9604 promoted fat loss without evidence of lean tissue catabolism — a distinguishing feature compared to caloric restriction or certain thermogenic compounds that can compromise muscle mass alongside fat stores.[1][2]

The preservation of lean tissue mass in AOD-9604-treated animals is consistent with the compound’s non-engagement of the GH receptor and absence of IGF-1 effects. While full hGH has well-documented anabolic properties alongside its lipolytic action, AOD-9604 offers a cleaner metabolic profile by isolating the fat-specific signal — though it also lacks the direct anabolic support that compounds like BPC-157 or TB-500 provide through different mechanisms.

The absence of insulin or glucose disruption is another relevant factor for body recomposition evaluation. Compounds that impair insulin sensitivity can compromise nutrient partitioning — concerns absent from AOD-9604’s preclinical profile. However, these observations derive from animal models, and the limited human efficacy data means body recomposition applications remain theoretical rather than clinically validated.

Injury & Tissue Support Context

The injury and tissue support angle for AOD-9604 is the newest and least established of its research directions. Kwon and Park (2015) conducted a study in a rabbit osteoarthritis model examining intra-articular AOD-9604, both alone and combined with hyaluronic acid. Results demonstrated potential chondroprotective effects, with histological evidence suggesting cartilage integrity support in joint-degeneration contexts.[4]

Rahman et al. (2026) reviewed therapeutic peptides in orthopaedic applications, including AOD-9604, positioning it within a growing category of peptide-based approaches to musculoskeletal repair while acknowledging the preliminary nature of the evidence.[5] This contrasts with more established tissue-repair peptides like BPC-157 and TB-500, which have substantially larger preclinical evidence bases.

The cartilage repair mechanism for AOD-9604 is not fully characterised. It may relate to broader signalling properties beyond lipolysis, or involve distinct peptide-receptor interactions in chondrocyte populations. At present, the evidence is limited to a single animal model study plus review commentary — insufficient for high-confidence conclusions but sufficient to justify continued research interest.

AOD-9604 Benefits

Documented aod 9604 benefits in the published research literature, framed by evidence quality:

• Lipolytic activity without GH-receptor engagement: stimulates fat oxidation and inhibits lipogenesis through beta-3 adrenergic receptor pathways, independent of classical growth hormone signalling.[1][2]
• No effect on IGF-1, glucose, or insulin: preclinical studies show no disruption of insulin sensitivity, blood glucose homeostasis, or IGF-1 levels — a cleaner metabolic profile than full hGH.[3]
• Preclinical fat oxidation data: consistent weight loss and fat oxidation enhancement demonstrated in obese mouse models over chronic treatment.[1][2]
• Safety demonstrated in human clinical trials: Phase 2 trials showed AOD-9604 was well-tolerated across multiple safety endpoints, even though efficacy was inconsistent.
• Emerging cartilage repair interest: a rabbit osteoarthritis model demonstrated potential chondroprotective effects, opening a secondary research avenue.[4]
• No growth-promoting effects: unlike full hGH, AOD-9604 does not stimulate tissue growth, organ enlargement, or skeletal changes — narrowing its effect profile to fat metabolism specifically.
• WADA-listed compound: inclusion on the WADA prohibited list indicates recognition of biological activity by international anti-doping authorities.[6]

AOD-9604 Side Effects

For aod 9604 side effects assessment, AOD-9604 has demonstrated a generally favourable safety profile across both preclinical and clinical research:

• No significant glucose metabolism effects: unlike full hGH, AOD-9604 did not impair glucose tolerance or insulin sensitivity in preclinical studies.[3]
• No IGF-1 elevation: preclinical data shows no stimulation of IGF-1 production, eliminating the growth-factor-related concerns associated with full growth hormone administration.
• No growth-promoting effects: absence of GH-receptor engagement means AOD-9604 does not carry the acromegalic or organomegaly risks associated with chronic hGH exposure.
• Well-tolerated in Phase 2 trials: human clinical trials reported no serious adverse effects attributable to AOD-9604 across tested parameters.
• Limited long-term safety data: clinical trials were relatively short-duration. Long-term safety profiles remain uncharacterised.
• WADA prohibited: AOD-9604 appears on the World Anti-Doping Agency prohibited list. This reflects anti-doping policy classification, not a safety determination, but it indicates regulatory scrutiny of the compound’s biological activity.[6]

The overall safety picture: AOD-9604 appears to have a more benign side-effect profile than full-length hGH, consistent with its narrower mechanism. However, limited long-term data and modest scope of human trials mean this assessment remains provisional.

Half-Life

The AOD 9604 peptide’s estimated half-life is approximately 30 minutes, consistent with the pharmacokinetic profile expected of a small peptide fragment. The rapid clearance reflects the compound’s low molecular weight (1815 g/mol) and susceptibility to proteolytic degradation — characteristics shared with other short-chain peptides like GHRP-6 and ipamorelin.

Cox et al. (2015) characterised AOD-9604’s in vitro metabolism and detection parameters, providing data relevant to pharmacological profiling and anti-doping detection windows.[6] The rapid clearance kinetics distinguish AOD-9604 from longer-acting modified peptides such as CJC-1295 with DAC, which employ structural modifications to extend half-life.

Limits of Current Evidence

AOD-9604’s evidence base has specific structural limitations that should calibrate interpretation:

• Phase 2 obesity trials did not advance: despite safety confirmation, human efficacy data for weight loss was insufficient to justify Phase 3 progression. This is the most significant evidence gap for aod 9604 weight loss claims.
• Predominantly preclinical data: the strongest efficacy evidence comes from obese mouse and rat models. Rodent-to-human translation for metabolic compounds has a well-documented failure rate.
• Limited cartilage repair evidence: the joint health data derives from a single rabbit osteoarthritis model.[4] This is preliminary, not confirmatory.
• No FDA approval: AOD-9604 received IND status for Phase 2b obesity trials but did not progress through the regulatory pathway. It is not approved for any clinical indication.
• Preclinical-to-clinical translation gap: the robust lipolytic effects observed in animal models did not translate to consistent weight loss in human trials. This gap is the defining limitation of AOD-9604’s evidence profile.
• Limited independent replication: much of the core preclinical data comes from a concentrated group of researchers affiliated with Metabolic Pharmaceuticals. Broader independent replication is sparse.

Verdict

This AOD 9604 review examines the full evidence base for a pharmacologically elegant concept: isolating human growth hormone’s lipolytic domain from its growth-promoting and diabetogenic effects. The preclinical data supports genuine fat-metabolism activity through a non-GH-receptor pathway involving beta-3 adrenergic signalling. The compound demonstrably promotes fat oxidation and inhibits lipogenesis in animal models without affecting IGF-1, insulin, or glucose homeostasis.[1][2][3]

However, translation from preclinical promise to human efficacy has been this AOD peptide’s central challenge. Phase 2 obesity trials confirmed safety but did not deliver the efficacy signal needed to advance. This is not unusual — many preclinical metabolic leads fail in human translation — but it should anchor realistic expectations.

The emerging cartilage repair data adds a secondary dimension of interest, though it remains too early to draw conclusions from a single rabbit model.[4][5] AOD-9604 is one of the most discussed peptides in the research community, driven more by conceptual appeal than validated clinical outcomes. For goal-specific context, evaluate against Fat Loss & Recomp, Body Recomp, and Injury & Tissue Support. For related compounds, see HGH Fragment 176-191 and tesamorelin. For the full research hub, visit Research.

FAQ

What is AOD-9604?

What is AOD 9604? AOD-9604 (Anti-Obesity Drug 9604) is a synthetic modified fragment of human growth hormone — specifically hGH fragment 176 191 — corresponding to amino acids 177–191 with an added N-terminal tyrosine. It was developed to isolate hGH’s fat-metabolism properties from its growth-promoting and insulin-disrupting effects. Research classification: lipolytic peptide.[1][3]

Is AOD-9604 the same as HGH?

No. This AOD peptide is a 16-amino-acid fragment of the 191-amino-acid hGH molecule. It does not bind the GH receptor, does not stimulate IGF-1 production, and does not promote growth. It selectively mimics the lipolytic (fat-metabolism) domain of hGH through a distinct beta-3 adrenergic receptor pathway.[2][3]

Does AOD-9604 affect insulin or blood sugar?

Preclinical research indicates that AOD-9604 does not affect blood glucose levels, insulin sensitivity, or insulin secretion — a key distinction from full-length human growth hormone, which has well-documented diabetogenic effects at sustained exposure levels.[3]

Is AOD-9604 FDA approved?

AOD-9604 is not FDA approved for any indication. It received Investigational New Drug (IND) status for Phase 2b obesity trials but did not advance to Phase 3. It is not a controlled substance but is prohibited by WADA for competitive sport.[6]

Does AOD-9604 actually work for fat loss?

Preclinical data in obese mouse models shows consistent fat oxidation enhancement and weight loss with chronic AOD-9604 treatment.[1][2] However, human Phase 2 clinical trials showed safety but modest and inconsistent efficacy signals for weight loss. The gap between preclinical promise and clinical outcome remains significant — aod 9604 fat loss evidence is stronger in animal models than in human data.

What is the difference between AOD-9604 and HGH Fragment 176-191?

AOD-9604 is a modified version of hGH fragment 176-191 (also written hGH fragment 176 191 or frag 176 191) with an additional tyrosine residue at the N-terminus. This modification was introduced to improve the peptide’s stability and lipolytic activity. The terms are sometimes used interchangeably in informal contexts, but they are structurally distinct compounds. For the unmodified fragment, see HGH Fragment 176-191.

Is AOD-9604 banned in sport?

Yes. AOD-9604 is included on the World Anti-Doping Agency (WADA) prohibited list. Cox et al. (2015) developed detection and metabolism methods specifically for anti-doping surveillance of AOD-9604.[6] WADA prohibition reflects regulatory classification of biological activity, not necessarily a safety determination.

References

1. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes. 2001;25(10):1442–1449. PMID: 11673763
2. Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189. PMID: 11713213
3. Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–278. PMID: 11146367
4. Kwon DR, Park GY. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426–432. PMID: 26275694
5. Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMID: 41490200
6. Cox HD, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31–38. PMID: 25208511